Seattle startup HDT Bio raises $3M to support development of COVID-19 vaccine

Share:

Seattle-based biotech company HDT Bio raised $3 million in seed funding to support work on its COVID-19 vaccine candidate that uses a cutting-edge, replicating RNA approach. The new funding will allow HDT Bio to add staff who have experience in clinical disease trials. The company is hoping to start a clinical trial of the vaccine in human volunteers in Brazil this October, with subsequent trials in the U.S. and India potentially launching in November. Read the story at GeekWire Ā»

Share: